Nasdaq adds Moderna to Nasdaq-100; Vaccine partnership with Merck KGaA advances
What happened
Nasdaq Inc. added Moderna to its Nasdaq-100 index earlier this month. In related news, Moderna is combining its vaccine with a drug from Merck KGaA as part of their strategic partnership to develop personalized mRNA cancer vaccines.
From fool.com
Why it matters
The inclusion in the Nasdaq-100 index prompts fund managers overseeing related exchange-traded funds to purchase Moderna stock. The partnership between Moderna and Merck KGaA is focused on jointly developing and testing personalized mRNA cancer vaccines.
From fool.com
Who's involved
- ModernaAmerican biotechnology company involved in vaccine development and index inclusion.
- NasdaqAmerican stock exchange that added Moderna to its Nasdaq-100 index.
- Merck KGaAGerman multinational company partnering with Moderna on cancer vaccine development.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ModernaSpeculative
Moderna could see increased institutional investment, which might make shares more expensive for ordinary investors to buy.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Morgan Stanley may adjust coverage after Moderna's Nasdaq-100 inclusionMorgan Stanley may revise ratings following Moderna's Nasdaq inclusion and drug partnershipLikely
- Moderna's vaccine combination increases competition for Eli LillyIncreased competitive pressure in advanced drug development for Eli LillyPossible
- FDA may review new Moderna-Merck combination drugFDA must evaluate new Moderna-Merck combination drug for melanoma treatmentPossible
- Moderna's cancer vaccine progress could challenge Pfizer's market positionModerna's advanced cancer vaccine and index inclusion may increase competitive pressure on PfizerPossible
Keep exploring
The entities involved
-
Moderna
American biotechnology company
-
Nasdaq
American fully electronic stock exchange
-
Merck KGaA
German multinational science and technology company
Related events
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- ProShares Ultra Top QQQ is a fund designed to deliver the performance of the Nasdaq 100 index.
- Moderna and Merck developed the intismeran autogene therapy.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.